ProfileGDS5678 / 1442571_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 61% 60% 59% 57% 58% 62% 63% 59% 59% 59% 59% 59% 60% 60% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6639261
GSM967853U87-EV human glioblastoma xenograft - Control 23.5663260
GSM967854U87-EV human glioblastoma xenograft - Control 33.5587459
GSM967855U87-EV human glioblastoma xenograft - Control 43.4119157
GSM967856U87-EV human glioblastoma xenograft - Control 53.4689258
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.7918462
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8534463
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5418659
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.546359
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.5302659
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.5595859
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5072859
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.589260
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5699660